Alterations of Thymus-Derived Tregs in Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
; 11(4): e200251, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-38838284
ABSTRACT
BACKGROUND AND OBJECTIVES:
Multiple sclerosis (MS) is considered a prototypic autoimmune disease of the CNS. It is the leading cause of chronic neurologic disability in young adults. Proinflammatory B cells and autoreactive T cells both play important roles in its pathogenesis. We aimed to study alterations of regulatory T cells (Tregs), which likely also contribute to the disease, but their involvement is less clear.METHODS:
By combining multiple experimental approaches, we examined the Treg compartments in 41 patients with relapsing-remitting MS and 17 healthy donors.RESULTS:
Patients with MS showed a reduced frequency of CD4+ T cells and Foxp3+ Tregs and age-dependent alterations of Treg subsets. Treg suppressive function was compromised in patients, who were treated with natalizumab, while it was unaffected in untreated and anti-CD20-treated patients. The changes in natalizumab-treated patients included increased proinflammatory cytokines and an altered transcriptome in thymus-derived (t)-Tregs, but not in peripheral (p)-Tregs.DISCUSSION:
Treg dysfunction in patients with MS might be related to an altered transcriptome of t-Tregs and a proinflammatory environment. Our findings contribute to a better understanding of Tregs and their subtypes in MS.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T Reguladores
/
Esclerose Múltipla Recidivante-Remitente
/
Natalizumab
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article